Feb 14 (Reuters) - SENSORION SA:
* SENS-401 RESULTS SUGGEST DAILY DURATION OF DRUG EXPOSURE IS MORE IMPORTANT THAN MAXIMAL DOSE EXPOSURE
* 28-DAY SENS-401 TREATMENT PROVIDES BETTER HEARING OUTCOME THAN A 14-DAY TREATMENT
* PHASE 1 CLINICAL TRIAL SHOWS SENS-401 IS WELL TOLERATED
* TRIAL SHOWS SENS-401 PHARMACOKINETIC PROFILE CONFORMS TO EXPOSURES NEEDED FOR PRECLINICAL EFFICACY
* INTENDS TO START PHASE 2 STUDY WITH SENS-401 IN THIS INDICATION DURING H1 2018‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
